Early Discharge of Patients with Pulmonary Embolisms From the Emergency Department with Rivaroxaban.

What we are studying

The purpose of this study is to compare the effects (both good and bad) of a blood thinning medication called rivaroxaban, to the effects of standard treatment at the hospital for patients who have a blood clot in their lung, called a pulmonary embolism (PE). Standard treatment follows the hospital’s current guidelines, which usually includes being admitted to the hospital and receiving medications that treat the blood clot in your lung. The medications that may be given as part of standard treatment for your PE are called anticoagulants, or blood thinners. This study is designed to show that it is safe to treat patients with a pulmonary embolism (PE) whose condition has a low risk of worsening, by taking rivaroxaban at home without being admitted to the hospital.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Must be seen in the Emergency Department and have a confirmed acute pulmonary embolism
  • Must be at low risk worsening medical condition
  • Must not be pregnant or become pregnant
  • Must be hemodynamically stable
  • Must not have any contraindications to the study medication

What is involved

  • Eligible participants will be randomized to one of two treatment groups: 1) Rivaroxaban and discharge
  • Or 2) Standard care. Those in the Rivaroxaban and Discharge group
  • Will be given rivaroxaban to take for about 90 days at home
  • While those in the Standard Care group will receive care according to the standard treatment guidelines for pulmonary embolisms at the hospital which usually includes being admitted to the hospital and receiving a blood thinner medication. Both treatment groups will have 3 follow-up telephone calls and 2 follow-up visits at the hospital. All participants will also be invited to participate in an optional biomarker study
  • In which 2 blood samples will be drawn about 2 hours apart. The blood samples will be de-identified and sent to a designated laboratory for testing.


Participants will receive $58.00 for each in person study visit to help with expenses like travel and parking expenses.

Contact Information

Study Coordinator
Stephanie Elliott

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.